Breakthrough CBD research

Breakthrough cbd research paves the way towards patient friendly therapies

dsm-firmenich present the first worldwide results comparing their novel CBD formulation CBtru® to Epidiolex.

This Phase I clinical trial shows CBtru® offers equivalent or better bioavailability than the current gold standard, with less variability between subjects and reduced food dependency. This solid formulation breakthrough could transform CBD medication delivery with more convenient dosage options and improved patient experience.

Speaker:

  • Athanasia Kanli - Sr. Director, Global Marketing Pharma, dsm-firmenich

This session lasts 20 min.

Related content

Related articles

  • Elevating patient care with smart science and superior services

    Elevating patient care with smart science and superior services

    Explore how dsm-firmenich can help pharma raise the bar in patient-centricity and sustainability.

  • Ask-the-expert: What’s next for pharma regulations in Asia-Pacific?

    Ask-the-expert: What’s next for pharma regulations in Asia-Pacific?

    Discover the top 5 trends transforming pharma regulations in Asia-Pacific and how drug developers can navigate this evolving landscape with dsm-firmenich.

  • dsm-firmenich’s API portfolio elevated by Verilege™

    dsm-firmenich’s API portfolio elevated by Verilege™

    Simplify the drug approvals process with Verilege™, an expert services platform offering regulatory, quality, sustainability, and supply chain support for APIs.

How can we help you?

  • New partnership request

    Have an idea for a new project, a groundbreaking innovation, or a need for expert services? Let’s talk.

  • Sample request

    Don’t just take our word for it. Discover how our solutions can support your product development journey. 

  • Quote request

    Tell us about your project needs. We’ll build you a tailored quote.